Nilotinib is a tyrosine kinase inhibitor (TKI) used primarily in the treatment of chronic myeloid leukemia (CML). It is designed to inhibit the BCR-ABL protein, which promotes cancer cell growth. Nilotinib is marketed under the brand name Tasigna and is approved by the FDA for use in adults.
